Elagolix as an oral substitute for injectable GnRH antagonists in IVF: a review and recent developments
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20264038Keywords:
Elagolix, Oral GnRH antagonist, In vitro fertilization, LH surge suppressionAbstract
During controlled ovarian stimulation for in vitro fertilization (IVF), a luteinizing hormone (LH) surge can trigger the release of a premature oocyte before scheduled oocyte retrieval. Suppressing this surge is critical in order to achieve a successful round of IVF. Gonadotropin Releasing Hormone (GnRH) antagonists bind to the GnRH receptor in the pituitary gland and prevent endogenous GnRH from stimulating LH release. This is a rapid and reversible blockade used by clinicians to enable successful IVF outcomes. Traditionally, injectable antagonist agents like ganirelix/cetrorelix have been popular but are reported as painful and expensive. Recently, new literature regarding the use of elagolix, an oral non-peptide GnRH antagonist, as a potentially less invasive and cheaper alternative has been published. This review critically appraises the present evidence on elagolix as an oral alternative for LH surge suppression in IVF. A literature search was conducted using PubMed as the primary database, supplemented by Google Scholar to identify additional relevant sources. Search terms included combinations of phrases like “elagolix,” “IVF,” “GnRH antagonist,” “ovarian stimulation,” “ganirelix,” “cetrorelix,” “HPO axis.” Studies were included if they reported original data or reviewed existing evidence on GnRH antagonist use in the context of ovarian stimulation for IVF. Studies examining elagolix’s use in the management of endometriosis-associated pain were also included. Reference lists of identified studies were further reviewed to pull additional relevant information. This search yielded additional studies that met the inclusion criteria. Across the available studies, elagolix demonstrates comparable LH suppression to injectable GnRH antagonists, offering a reduced injection and per-cycle cost burden for IVF patients. However, this evidence is limited to a small number of majorly retrospective and a few prospective cohort studies. No randomized controlled trials have been published to date. Dosage and safety data relevant to elagolix’s use in IVF also remains scarce. According to our analysis, elagolix shows promise, but larger clinical trials and prospective studies are needed to solidify elagolix as a cost-effective and hypoalgesic alternative.
Metrics
References
Kauffman AS. Neuroendocrine mechanisms underlying estrogen positive feedback and the LH surge. Front Neurosci. 2022;16:953252. DOI: https://doi.org/10.3389/fnins.2022.953252
Christian CA, Moenter SM. The neurobiology of preovulatory and estradiol-induced gonadotropin-releasing hormone surges. Endocr Rev. 2010;31(4):544-77. DOI: https://doi.org/10.1210/er.2009-0023
Baldini GM, Baldini D, Lot D, Ferri D, Malvasi A, Fioretti B, et al. The trigger in IVF cycles: molecular pathways and clinical implications. Int J Mol Sci. 2025;26(24):11962. DOI: https://doi.org/10.3390/ijms262411962
Soliman D, Naoom R, Zaied M, Soliman S. The role of elagolix in ovulation suppression during controlled ovarian stimulation: a retrospective cohort study. F S Rep. 2024;5(4):356-62. DOI: https://doi.org/10.1016/j.xfre.2024.06.006
Aldarsooni M, Alfarah M, Albohammod F, Al-Jaroudi D. Effect of premature luteinizing hormone surge on pregnancy outcomes in intracytoplasmic sperm injection or in vitro fertilization cycles. Front Med (Lausanne). 2025;11:1429033. DOI: https://doi.org/10.3389/fmed.2024.1429033
Kumar P, Sharma A. Gonadotropin-releasing hormone analogs: understanding advantages and limitations. J Hum Reprod Sci. 2014;7(3):170-4. DOI: https://doi.org/10.4103/0974-1208.142476
Diedrich K, Diedrich C, Santos E, Zoll C, Al-Hasani S, Reissmann T, et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation. Hum Reprod. 1994;9(5):788-91. DOI: https://doi.org/10.1093/oxfordjournals.humrep.a138597
The Ganirelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod. 1998;13(11):3023-31. DOI: https://doi.org/10.1093/humrep/13.11.3023
Mouanness M, Merhi Z. Elagolix represents a less invasive and cheaper option than injectable GnRH antagonist for ovulation suppression in IVF. J Clin Endocrinol Metab. 2025;110(2):e456-60. DOI: https://doi.org/10.1210/clinem/dgae168
Lamb YN. Elagolix: first global approval. Drugs. 2018;78(14):1501-8. DOI: https://doi.org/10.1007/s40265-018-0977-4
Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28-40. DOI: https://doi.org/10.1056/NEJMoa1700089
Ezzati M, Carr BR. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond). 2015;11(1):19-28. DOI: https://doi.org/10.2217/WHE.14.68
Archer DF, Ng J, Chwalisz K, Chiu YL, Feinberg EC, Miller CE, et al. Elagolix suppresses ovulation in a dose-dependent manner: results from a 3-month, randomized study in ovulatory women. J Clin Endocrinol Metab. 2020;105(3):821-32. DOI: https://doi.org/10.1210/clinem/dgz086
Taylor HS, Dun EC, Chwalisz K. Clinical evaluation of the oral gonadotropin-releasing hormone-antagonist elagolix for the management of endometriosis-associated pain. Pain Manag. 2019;9(5):497-515. DOI: https://doi.org/10.2217/pmt-2019-0010
Boniface C, Schnorr JN, Gray J, McLaughlin J, Cook H, Slowey M, et al. The role of elagolix in the suppression of ovulation in donor oocyte cycles. F S Rep. 2023;4(2):179-82. DOI: https://doi.org/10.1016/j.xfre.2023.03.006
Grisendi V, Grandi G, Capuzzo M, La Marca A. The use of oral GnRH antagonists to inhibit the LH surge in women undergoing ovarian stimulation for in vitro fertilization. Expert Rev Clin Pharmacol. 2024;17(12):1089-91. DOI: https://doi.org/10.1080/17512433.2024.2428342
Taylor HS, Soliman AM, Johns B, Pokrzywinski RM, Snabes M, Coyne KS. Health-related quality of life improvements in patients with endometriosis treated with elagolix. Obstet Gynecol. 2020;136(3):501-9. DOI: https://doi.org/10.1097/AOG.0000000000003917
Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, et al. Long-term outcomes of elagolix in women with endometriosis: results from two extension studies. Obstet Gynecol. 2018;132(1):147-60. DOI: https://doi.org/10.1097/AOG.0000000000002675
Ali M, Sara AR, Al Hendy A. Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Rev Clin Pharmacol. 2021;14(4):427-37. DOI: https://doi.org/10.1080/17512433.2021.1900726
US Food and Drug Administration. Orilissa (elagolix) tablets: supplement approval letter. Silver Spring (MD): US Food and Drug Administration; 2023. Available from: https://www.accessdata.fda.gov/ drugsatfda_docs/appletter/2023/210450Orig1s009ltr.pdf Accessed on 05 August 2026.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Jaina Modi

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.